Rennova Health, Inc. (NASDAQ:RNVA) Files An 8-K Unregistered Sales of Equity Securities

Rennova Health, Inc. (NASDAQ:RNVA) Files An 8-K Unregistered Sales of Equity Securities
Item 3.02. Unregistered Sales of Equity Securities.

Story continues below

As previously announced, the Additional Issuance Agreements entered into by Rennova Health, Inc. (the “Company”) on July 16, 2018 provided that, from time to time on or before December 31, 2018, in one or more closings, the Company may request that the institutional investors party to the Additional Issuance Agreements purchase up to $3,100,000 aggregate principal amount of additional Senior Secured Original Issue Discount Convertible Debentures due September 19, 2019, issuable under the Additional Issuance Agreements. As also previously announced, on August 2, 2018 the institutional investors purchased $620,000 aggregate principal amount of additional Debentures and the Company received proceeds of $500,000.

The Company requested that the institutional investors purchase a further $1,240,000 aggregate principal amount of Debentures, which was accepted by the investors. The Debentures were issued on September 6, 2018 and the Company received proceeds of $1,000,000. After the issuances on August 2, 2018 and September 6, 2018, under the Additional Issuance Agreements the Company may now request that the institutional investors purchase up to $1,240,000 aggregate principal amount of additional Debentures on or before December 31, 2018.

These Debentures were issued in reliance on the exemption from registration contained in Section 4(a)(2) of the Securities Act of 1933, as amended, and by Rule 506 of Regulation D promulgated thereunder as a transaction by an issuer not involving a public offering.


About Rennova Health, Inc. (NASDAQ:RNVA)

Rennova Health, Inc. (Rennova), formerly CollabRx, Inc., is a provider of diagnostics and supportive software solutions to healthcare providers. The Company operates in three segments: clinical laboratory operations, supportive software solutions, and decision support and informatics operations. The Company is a healthcare enterprise that delivers products and services, including laboratory diagnostics, healthcare technology solutions, and revenue cycle management and intends to provide financial services, to medical providers. Rennova’s principal line of business is clinical laboratory blood and urine testing services. It is also engaged in the provision of urine drug toxicology testing to physicians, clinics and rehabilitation facilities in the United States. Its clinical laboratories include Biohealth Medical Laboratory, Inc.; Alethea Laboratories, Inc.; International Technologies, LLC; EPIC Reference Labs, Inc., and Epinex Diagnostics Laboratories, Inc.

An ad to help with our costs